A nasal spray to treat severe allergic reactions

In United States, the Food and Drug Administration (FDA) has just approved a new drug for the treatment of severe allergic reactions.

The neffy® device is a nasal spray to use during an episode of anaphylaxis and is suitable for adults and children weighing at least 30 kg (66 lbs).

This is the first treatment to enable needle-free administration of epinephrine.  It has a shelf life of 30 months, and the device protects the medication from wide temperature variations (up to 50°C) and withstands exposure below freezing.

Available in U.S. pharmacies in October 2024, it will be at least another year before neffy® is available here in Canada.

Allergies Québec spoke earlier this week with Richard Lowenthal, CEO and President of ARS Pharmaceuticals, who tells us that an application will be filed with Health Canada later this year.  The product should be available in Canada towards the end of 2025, depending on how long it takes to process the application.

For the allergy community, this innovative product represents a real step forward.

We’ll keep you posted on further developments!